Showing 8711-8720 of 20877 results for "".
Breaking the Cycle: Prioritizing Weight Loss to Improve OSA Management
https://reachmd.com/programs/cme/breaking-the-cycle-prioritizing-weight-loss-to-improve-osa-management/48715/On-demand webcast of expert faculty presentation on the connection between obstructive sleep apnea (OSA) and obesity, including strategies for prioritizing weight loss to improve OSA management among select patients.Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers
https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patiPrecision Starts Before Birth: Reimagining Fetal Care Through FcRn Immune Modulation
https://reachmd.com/programs/cme/Precision-Starts-Before-Birth-Reimagining-Fetal-Care-Through-FcRn-Immune-Modulation/37099/Explore FcRn inhibition as a preventive strategy for HDFN and FNAIT, with focus on ongoing trials including AZALEA and FREESIA.Decoding Itch in CKD: From CKD-aP Suspicion to Solution
https://reachmd.com/programs/cme/decoding-itch-in-ckd-from-ckd-ap-suspicion-to-solution/26640/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 6
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-6/56874/In the sixth installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, discuss patient adherence, tolerability, and the importance of simple, non-irritating regimens in achieving real-world success.1 Draelos Z, HougeirRaising the Bar for Hodgkin Lymphoma: Optimizing Immunotherapy in Community Practice
https://reachmd.com/programs/cme/raising-the-bar-for-hodgkin-lymphoma-optimizing-immunotherapy-in-community-practice/56816/This online activity is designed to provide the healthcare team with the latest developments and critical insights into Hodgkin lymphoma treatment. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clIBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
https://reachmd.com/programs/cme/ibd-masterclass-choosing-the-right-ibd-therapy-a-patient-clinician-connection/54374/A case-based discussion of therapy selection, de-escalation, and treat-to-target approaches in inflammatory bowel disease management.Frontline Insights: Emerging Therapeutic Strategies in HNSCC
https://reachmd.com/programs/cme/Frontline-Insights-Emerging-Therapeutic-Strategies-in-HNSCC/49223/Review emerging therapeutic strategies in HNSCC across disease states and learn to compare safety profile to improve AE recognition, prevention, and management.The First Approved All-Oral, Fixed Duration Treatment for CLL: Insights from the AMPLIFY Trial
https://reachmd.com/programs/project-oncology/the-first-approved-all-oral-fixed-duration-treatment-for-cll-insights-from-the-amplify-trial/56747/The treatment landscape for first-line chronic lymphocytic leukemia (CLL) has evolved, with targeted therapies and fixed-duration approaches entering the conversation.1 With venetoclax/acalabrutinib, we have an all-oral, fixed-duration treatment option that doesn’t require infusions.2 The Phase 3 AMATTRibute-CM: Insights from ESC HF
https://reachmd.com/clinical-practice/cardiology/attribute-cm-insights-from-esc-hf/57173/Examine outpatient worsening heart failure in ATTR-CM and the clinical implications of data presented at ESC HF